INT184270

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 10.48
Pain Relevance 3.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (AGER) extracellular region (AGER) plasma membrane (AGER)
cytoplasm (AGER)
Anatomy Link Frequency
blood 1
AGER (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 390 99.56 Very High Very High Very High
Inflammation 188 99.00 Very High Very High Very High
cytokine 37 98.48 Very High Very High Very High
metalloproteinase 14 97.92 Very High Very High Very High
methotrexate 60 96.16 Very High Very High Very High
Bioavailability 4 95.64 Very High Very High Very High
Osteoarthritis 12 82.88 Quite High
Arthritis 24 77.40 Quite High
Inflammatory response 18 67.84 Quite High
Paracetamol 2 57.48 Quite High
Disease Link Frequency Relevance Heat
Hyperglycemia 113 99.84 Very High Very High Very High
Glioma 2 99.74 Very High Very High Very High
Cancer 277 99.60 Very High Very High Very High
Rheumatoid Arthritis 390 99.56 Very High Very High Very High
Skin Cancer 2 99.40 Very High Very High Very High
Pancreatic Cancer 2 99.10 Very High Very High Very High
INFLAMMATION 210 99.00 Very High Very High Very High
Metastasis 6 98.76 Very High Very High Very High
Diabetes Mellitus 112 98.72 Very High Very High Very High
Disease 155 97.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We conclude that a decreased level of sRAGE in patients with RA might increase the propensity towards inflammation, whereas treatment with methotrexate counteracts this feature.


Negative_regulation (decreased) of sRAGE associated with inflammation, rheumatoid arthritis and methotrexate
1) Confidence 0.32 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175032 Disease Relevance 1.35 Pain Relevance 0.57
An alternative explanation for the decreased sRAGE levels in RA might be a true consumption of this molecule.
Negative_regulation (decreased) of sRAGE associated with rheumatoid arthritis
2) Confidence 0.32 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175032 Disease Relevance 1.18 Pain Relevance 0.59
If it were the case, the decreased sRAGE levels found in our RA patient population would be explained by in vivo or ex vivo HMGB1 interaction.
Negative_regulation (decreased) of sRAGE associated with rheumatoid arthritis
3) Confidence 0.32 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175032 Disease Relevance 0.61 Pain Relevance 0.25
We conclude that a decreased level of sRAGE in patients with RA might increase the propensity towards inflammation, whereas treatment with methotrexate counteracts this feature.



Negative_regulation (decreased) of sRAGE associated with inflammation, rheumatoid arthritis and methotrexate
4) Confidence 0.32 Published 2005 Journal Arthritis Res Ther Section Abstract Doc Link PMC1175032 Disease Relevance 1.50 Pain Relevance 0.62
RA patients displayed significantly decreased blood levels of sRAGE (871 ± 66 pg/ml, P < 0.0001) as compared with healthy controls (1290 ± 78 pg/ml) and with patients with non-inflammatory joint disease (1569 ± 168 pg/ml).
Negative_regulation (decreased) of sRAGE in blood associated with inflammation, rheumatoid arthritis and arthropathy
5) Confidence 0.32 Published 2005 Journal Arthritis Res Ther Section Abstract Doc Link PMC1175032 Disease Relevance 1.70 Pain Relevance 0.66
It therefore has the ability to prevent RAGE signalling acting as a decoy by binding ligands and preventing them from reaching cell surface RAGE. sRAGE has successfully been used in variety of animal disease models to antagonize RAGE-mediated pathologic processes [5,14-16].
Negative_regulation (prevent) of RAGE associated with pathologic processes and animal disease models
6) Confidence 0.32 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175032 Disease Relevance 0.50 Pain Relevance 0.16
AGE-RAGE interaction has been shown to stimulate tumour cell growth or invasiveness in pancreatic cancer [67], melanoma [68], and glioma [69], while blocking the RAGE inhibits tumour formation and metastasis [68, 69].
Negative_regulation (blocking) of RAGE associated with cancer, pancreatic cancer, skin cancer, metastasis and glioma
7) Confidence 0.09 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2825545 Disease Relevance 1.12 Pain Relevance 0.09
In one study AGE-RAGE blockade decreased expression of inflammatory cytokines and MMPs resulting in normalization of wound closure in a genetic mouse model of diabetes [115].
Negative_regulation (blockade) of AGE-RAGE associated with inflammation, diabetes mellitus, injury, metalloproteinase and cytokine
8) Confidence 0.09 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2825545 Disease Relevance 1.46 Pain Relevance 0.42
Type 2 diabetics have lower sRAGE levels compared to nondiabetics, suggesting a downregulation of sRAGE in hyperglycemia.
Negative_regulation (downregulation) of sRAGE associated with hyperglycemia and diabetes mellitus
9) Confidence 0.00 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350125 Disease Relevance 1.06 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox